The go/kill decision is the point of entry into a new product development stage gate review that requires a decision from leaders on whether to move forward with a project, put it on hold or cut it loose-all in conjunction with decision criteria. It’s a decision driven by clarity around cost, risk and market dynamics that prevents a pharma or NPD portfolio from investing in projects that should have already been stopped.